A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703

Zachariah DeFilipp, Linda J. Burns, Samantha M. Jaglowski, Aaron L. Leppin, Steven Pavletic, Bryce Waldman, Daniel J. Weisdorf, William A. Wood, Nandita Khera

Research output: Contribution to journalComment/debatepeer-review

Abstract

Effective immunosuppressive regimens to prevent the development of graft-versus-host disease (GVHD) are essential to the success of allogeneic hematopoietic cell transplantation (HCT). After revolutionizing haploidentical transplantation, post-transplantation cyclophosphamide (PTCy) is now being evaluated for HCT performed from related and unrelated donors. In this setting, 2 recent randomized studies have demonstrated lower rates of GVHD and superior GVHD-free, relapse-free survival with PTCy compared with conventional GVHD prophylaxis. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is currently conducting a large, randomized phase III, multicenter trial (BMT CTN 1703) comparing PTCy/tacrolimus/mycophenolate mofetil to tacrolimus/methotrexate as GVHD prophylaxis regimens in reduced-intensity allogeneic HCT. Here we review the ongoing study, highlight its importance to the field, and explore the possible implications of its results on clinical practice.

Original languageEnglish (US)
Pages (from-to)e305-e308
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number12
DOIs
StatePublished - Dec 2020

Bibliographical note

Funding Information:
Financial disclosure: Support for this study was provided by National Heart, Lung, and Blood Institute, National Cancer Institute (NIH) Grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Funding Information:
The authors thank Janelle Olson, PhD for her support of the BMT CTN Task Force on Evidence into Practice and this report. Financial disclosure: Support for this study was provided by National Heart, Lung, and Blood Institute, National Cancer Institute (NIH) Grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page e308.

Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Graft-versus-host disease
  • Prophylaxis

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Review

Fingerprint

Dive into the research topics of 'A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703'. Together they form a unique fingerprint.

Cite this